1 BTC
=
- USD
Paysign, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Paysign, Inc. Common Stock
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
Market Statistics
Trading Metrics
How to Buy PAYS
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy PAYS
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesPaysign stock dropped 12.3% despite beating Q1 earnings expectations with 50.8% revenue growth and 80% EPS growth. The decline was triggered by management's decision to maintain prior guidance rather than raise it, disappointing investors after the stock had already rallied 35% year-to-date. At 23.5x forward earnings with nearly 100% projected earnings growth, analysts suggest the stock may be attractive at current levels, though small-cap risks remain.
Paysign (NASDAQ: PAYS) reported strong Q1 2026 results with 51% revenue growth to $28.04 million, driven by 82% pharma revenue growth and 25% plasma revenue growth. Net income nearly doubled to $5.44 million ($0.09 per share), with adjusted EBITDA up 113% to $10.59 million. The company added 45 net patient affordability programs (135 total) and 89 plasma centers (573 total), exceeding guidance across all metrics.
Paysign stock surged 35.8% on March 25, 2026, following strong Q4 earnings that beat sales expectations at $22.76M versus $21.55M forecast. The company projects 2026 revenue between $106.5M-$110.5M (32.5% growth) with net income of $13M-$16M, driven by momentum in pharmaceuticals and plasma verticals. Despite today's rally, the stock remains down roughly 1% year-to-date.
Paysign reported strong Q2 2025 earnings with 33.1% revenue growth, driven by robust pharma patient affordability programs, despite softening plasma revenue. The company raised its full-year guidance and showed significant profitability improvements.